GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
55.51
+1.00 (1.83%)
At close: Mar 9, 2026, 4:00 PM EDT
53.96
-1.55 (-2.79%)
After-hours: Mar 9, 2026, 7:32 PM EDT
GSK Revenue
In the year 2025, GSK had annual revenue of 32.67B GBP with 4.11% growth. GSK had revenue of 8.62B in the quarter ending December 31, 2025, with 6.17% growth.
Revenue (ttm)
32.67B GBP
Revenue Growth
+4.11%
P/S Ratio
2.50
Revenue / Employee
488,727 GBP
Employees
66,841
Market Cap
109.82B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.67B | 1.29B | 4.11% |
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
GSK News
- 14 hours ago - Former GlaxoSmithKline HQ in west London to be transformed into 1,500 new homes - Evening Standard
- 19 hours ago - GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million - WSJ
- 19 hours ago - GSK: Alfasigma To Acquire Rights To Develop, Manufacture, Commercialise Linerixibat - Nasdaq
- 19 hours ago - GSK licenses liver disease drug to Italy's Alfasigma - Reuters
- 4 days ago - Pay bonanza for blue chip bosses: Rolls-Royce chief 'Turbo' Tufan set for £24m as GSK's Walmsley scoops £15.7m - This is Money
- 4 days ago - Emma Walmsley’s pay rose almost 50% to £15.6m in final year as GSK boss - The Guardian
- 5 days ago - SCYNEXIS Posts Narrower FY25 Loss, Advances Next-Gen Antifungal Pipeline - Nasdaq
- 5 days ago - SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - Benzinga